Long-term efficacy and safety of personalized P2Y<sub>12</sub> receptor antagonists according to CYP2C19 genotype for patients with acute coronary syndrome or undergoing percutaneous coronary intervention： a Meta-analysis

doi:10.3969/j.issn.1672-3384.2022.01.005

Long-term efficacy and safety of personalized P2Y₁₂ receptor antagonists according to CYP2C19 genotype for patients with acute coronary syndrome or undergoing percutaneous coronary intervention： a Meta-analysis

FANG Zhen-wei, SHI Xiu-jin, ZHAO Zi-nan, DING Zheng, WEI Juan-juan, ZHOU Yang, LIN Bai-di, ZHOU Peng-xiang, LIN Yang

Clinical Medication Journal ›› 2022, Vol. 20 ›› Issue (1) : 43-52.

PDF(1182 KB)

Clinical Medication Journal ›› 2022, Vol. 20 ›› Issue (1) : 43-52. DOI: 10.3969/j.issn.1672-3384.2022.01.005

Original Article

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 20(1): 43-52 https://doi.org/10.3969/j.issn.1672-3384.2022.01.005

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(1182 KB)

Accesses

Citation

Detail

Sections

Recommended

Please choose a citation manager

Content to export